CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 397 enrolled
Drug / intervention
semaglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02305381
NCT02305381Phase 3Completed
CompareCT.gov

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

Novo Nordisk A/S·interventional·Posted Dec 2, 2014·Updated Jun 11, 2019

In Brief

A Phase 3 clinical trial evaluating semaglutide and placebo for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 397 participants across 99 sites in 6 countries.

Detailed Summary

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide once weekly versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in subjects with type 2 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesGermany, Japan, Puerto Rico, Serbia, Slovakia, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2, 2014
Enrollment StartDec 1, 2014
Primary CompletionNov 21, 2015
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 11.6 years ago

Interventions

semaglutidedrug

Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.

placebodrug

Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.